Equities

Bicycle Therapeutics PLC

Bicycle Therapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)25.43
  • Today's Change-0.07 / -0.27%
  • Shares traded99.94k
  • 1 Year change+17.79%
  • Beta0.8847
Data delayed at least 15 minutes, as of Sep 20 2024 16:16 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy4
Outperform7
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Bicycle Therapeutics PLC (ADR) have a median target of 38.00, with a high estimate of 56.00 and a low estimate of 28.00. The median estimate represents a 49.02% increase from the last price of 25.50.
High119.6%56.00
Med49.0%38.00
Low9.8%28.00

Earnings history & estimates in USD

On Aug 06, 2024, Bicycle Therapeutics PLC (ADR) reported 2nd quarter 2024 losses of -0.77 per share. This result exceeded the -1.10 consensus loss of the 12 analysts covering the company and exceeded last year's 2nd quarter results by 45.39%.
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate+10.23%
Bicycle Therapeutics PLC (ADR) reported annual 2023 losses of -5.08 per share on Feb 20, 2024.
Average growth rate-18.10%
More ▼

Revenue history & estimates in USD

Bicycle Therapeutics plc had 2nd quarter 2024 revenues of 9.36m. This bettered the 6.17m consensus of the 11 analysts covering the company. This was 91.20% above the prior year's 2nd quarter results.
Average growth rate+40.21%
Bicycle Therapeutics plc had revenues for the full year 2023 of 26.98m. This was 86.52% above the prior year's results.
Average growth rate+24.51%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.